Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Gerritsen

Showing results (181-190 of 224) with videos related to

Pageof 23
Sort By:
European Urology|August 22, 2024
Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 TrialRonald de Wit, David J Vaughn, Yves Fradet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 2024
Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trialS van Wilpe, I S H Kloots, P H J Slootbeek, et al.
Oncoimmunology|March 5, 2016
Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccinationKalijn F Bol, Erik H J G Aarntzen, Florentien E M In 't Hout, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 22, 2025
Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with <sup>223</sup>Ra Therapy in Daily PracticeJoost H H M van Riel, Maarten L Donswijk, Christel Brouwer, et al.
International Journal of Cancer|May 17, 2014
Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survivalAlessandra De Remigis, Tanja D de Gruijl, Jennifer N Uram, et al.
Cancer Immunology, Immunotherapy : CII|August 11, 2012
T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatmentSaskia J A M Santegoets, Anita G M Stam, Sinéad M Lougheed, et al.
European Urology Oncology|September 6, 2023
Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial CancerSofie H Tolmeijer, Sandra van Wilpe, Maartje J Geerlings, et al.
Annals of Surgical Oncology|March 5, 2019
Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant TherapyMartine Bloemendal, Wouter W van Willigen, Kalijn F Bol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2005
Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patientsRosalie M Luiten, Esther W M Kueter, Wolter Mooi, et al.
International Journal of Cancer|September 23, 2020
Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancerPeter H J Slootbeek, Marleen L Duizer, Maarten J van der Doelen, et al.
Pageof 23

Showing results (181-190 of 224) with videos related to

Sort By:
Pageof 23
European Urology|August 22, 2024
Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 TrialRonald de Wit, David J Vaughn, Yves Fradet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 2024
Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trialS van Wilpe, I S H Kloots, P H J Slootbeek, et al.
Oncoimmunology|March 5, 2016
Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccinationKalijn F Bol, Erik H J G Aarntzen, Florentien E M In 't Hout, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 22, 2025
Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with <sup>223</sup>Ra Therapy in Daily PracticeJoost H H M van Riel, Maarten L Donswijk, Christel Brouwer, et al.
International Journal of Cancer|May 17, 2014
Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survivalAlessandra De Remigis, Tanja D de Gruijl, Jennifer N Uram, et al.
Cancer Immunology, Immunotherapy : CII|August 11, 2012
T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatmentSaskia J A M Santegoets, Anita G M Stam, Sinéad M Lougheed, et al.
European Urology Oncology|September 6, 2023
Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial CancerSofie H Tolmeijer, Sandra van Wilpe, Maartje J Geerlings, et al.
Annals of Surgical Oncology|March 5, 2019
Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant TherapyMartine Bloemendal, Wouter W van Willigen, Kalijn F Bol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2005
Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patientsRosalie M Luiten, Esther W M Kueter, Wolter Mooi, et al.
International Journal of Cancer|September 23, 2020
Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancerPeter H J Slootbeek, Marleen L Duizer, Maarten J van der Doelen, et al.
Pageof 23